Jump to main content

Knopp Biosciences

Knopp Biosciences

Knopp Biosciences seeks to discover, develop, and deliver breakthrough medicines for urgent unmet medical needs. Our goal is to accelerate and advance treatment, change the course of devastating diseases, and improve the lives of patients and their families.

Bold science. Breakthrough medicine.

Home Slide 6
Products and Platforms

Products and Platforms

  • Dexpramipexole in Immunology and Hematology

    Knopp is advancing dexpramipexole as an immunological therapeutic based on its preclinical and clinical activity in modulating white blood cells known as eosinophils.

  • Dexpramipexole in ALS

    Knopp is advancing dexpramipexole as a novel, oral investigational treatment for amyotrophic lateral sclerosis (ALS). ALS is a devastating disease of progressive paralysis with very limited treatment options.

  • Mitochondrial Discovery Platform

    The disruption of cellular bioenergetics has emerged as a common factor in pathways leading to cell death in ALS, Parkinson's, and other neurodegenerative disorders. Knopp is discovering novel small-molecule mediators of these pathways.

  • Ion Channel Discovery Platform

    Ion channels, or proteins that regulate the excitability of cells, represent an important class of drug targets in several neurological and cardiovascular conditions. Knopp is discovering novel compounds to modulate these channels.